Literature DB >> 16476292

[Celecoxib-induced aquagenic keratoderma].

Susana Vildósola1, Aitziber Ugalde.   

Abstract

Aquagenic keratoderma is an infrequent condition characterized by translucent, smooth-surfaced papules and plaques and prominent eccrine ducts. It is limited to the palms and appears or becomes more pronounced after exposure to water. Histopathologically, hyperkeratosis and dilation of the eccrine ducts are seen. This condition has been described in adolescents and young women. We present the case of a 31-year-old woman with rheumatoid arthritis who had begun treatment with celecoxib one month before the onset of her cutaneous symptoms. Similar changes have been described in association with cystic fibrosis, and a case induced by rofecoxib has also been reported. Higher levels of sodium in the skin associated with celecoxib could increase the keratin's ability to take in water, and this may cause the clinical symptoms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16476292     DOI: 10.1016/s0001-7310(05)73129-x

Source DB:  PubMed          Journal:  Actas Dermosifiliogr        ISSN: 0001-7310


  5 in total

1.  Unilateral aquagenic keratoderma treated with botulinum toxin A.

Authors:  Marie-Claude Houle; Rola Al Dhaybi; Antranik Benohanian
Journal:  J Dermatol Case Rep       Date:  2010-04-11

2.  Aquagenic keratoderma. Two new case reports and a new hypothesis.

Authors:  Georgi Tchernev; Kristina Semkova; José Carlos Cardoso; J Julian Ananiev; Uwe Wollina
Journal:  Indian Dermatol Online J       Date:  2014-01

3.  Watersport hands.

Authors:  Jeremy B Kent; Siobhan M Statuta; Kenneth E Greer; John M MacKnight
Journal:  Sports Health       Date:  2014-07       Impact factor: 3.843

4.  Aquagenic palmar wrinkling induced by combined use of salazopyrin and indomethacin.

Authors:  Ozgür Gündüz; Kivilcim Çinkir Ozsaraç; Mustafa Emre Ercin
Journal:  Case Rep Dermatol       Date:  2013-01-22

5.  Aquagenic syringeal acrokeratoderma.

Authors:  Belkiz Uyar
Journal:  Indian J Dermatol       Date:  2014-11       Impact factor: 1.494

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.